Nu Holdings Ltd vs Stryker Corporation — how do they compare? Nu Holdings Ltd trades at $15.6 (market cap $74.30B), while Stryker Corporation trades at $276.85 (market cap $106.24B). The key difference: Stryker Corporation is the larger of the two by market cap, and Stryker Corporation pays a 1.27% dividend while Nu Holdings Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nu Holdings Ltd for 53 Days and Stryker Corporation for 20 Days on average.
| NU | SYK | |
|---|---|---|
Market Cap | $74.30B | $106.24B |
Volume | 80,294,805 | 2,982,001 |
Sector | Financials | Health |
52-Week High | $18.76 | $388.35 |
52-Week Low | $11.60 | $269.75 |
Typical Hold Time | 53 Days | 20 Days |
Enterprise Value | $96.91B | $117.70B |
Dividend Yield | — | 1.27% |
Signals from Pluang's Aura AI — not financial advice
NU Holdings (NU) trades at $15.58, down 0.51% on the day, with strong fundamental momentum despite recent volatility. The stock shows bullish technical signals with moving averages supporting upward trends, while oscillators indicate some near-term pressure. Revenue growth has accelerated from $3.0B in 2022 to $10.6B in 2025, with net income turning positive and reaching $2.9B. Recent news highlights acquisition speculation and Goldman Sachs' bullish stance, though the company denied Monzo deal talks.
The outlook remains positive with 56.5% analyst buy ratings and a $16.53 consensus target offering 6% upside. Key opportunities include expanding Latin American digital banking penetration and strong profitability metrics (27.4% net margin). Risks include credit quality concerns from rising delinquencies and competitive pressures in fintech. The stock presents a growth opportunity but requires monitoring of execution risks and market sentiment shifts.
Stryker Corporation (SYK) trades at $275.40, down 1.11% amid bearish technical signals and recent negative news regarding manufacturing issues. The company maintains strong fundamentals with Q2 2026 EPS beating expectations at $3.69 versus $3.49 expected, and profitability metrics remain robust with a 14.43% net income margin. Analyst consensus remains overwhelmingly bullish with a $368.11 price target representing 33% upside potential.
Despite near-term headwinds from manufacturing disclosures and legal investigations, Stryker's solid earnings track record, strong cash flow generation, and dominant medical technology position support long-term growth prospects. Key risks include ongoing legal scrutiny and competitive pressures in the medtech sector.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Nu Holdings Ltd is engaged in providing digital banking services. It offers several financial services such as Credit cards, Personal Account, Investments, Personal Loans, Insurance, Mobile payments, Business Account, and Rewards.
Read more on NU →Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →